Global Clinical and Translational Research > 2022 Post Page > Pharmacovigilance Principles: The Building Blocks of Benefit-Risk Assessments
Pharmacovigilance Principles: The Building Blocks of Benefit-Risk Assessments
Rosa A. Piccirillo and Jennifer Parish
2022/10/14
A medicinal product must demonstrate a favorable benefit-risk balance to remain on the market. That the benefits of use outweigh the risks is established using analyses referred to as benefit-risk assessments, which are conducted on an ongoing basis throughout the lifecycle of a medicinal product. While fundamental to maintaining a product’s marketing authorization, few regulatory guidance documents have been developed to provide information on the specific content and structure of a benefit-risk assessment. This paper aims to provide an overview of the key concepts in pharmacovigilance that contribute to the creation of a structured benefit-risk assessment, particularly through qualitative analysis.
Reference
Piccirillo R and Parish J. Pharmacovigilance Principles: The Building Blocks of Benefit-Risk Assessments. Glob Clin Transl Res. 2022; 4(4): 1-7. DOI:10.36316/gcatr.04.0045.
